Valuation: Jazz Pharmaceuticals plc

Capitalization 7.47B 7.22B 6.81B 6.01B 10.68B 648B 11.86B 81.11B 30.1B 269B 27.98B 27.43B 1,137B P/E ratio 2024 *
15.2x
P/E ratio 2025 * 12.7x
Enterprise value 10.91B 10.55B 9.96B 8.78B 15.61B 947B 17.33B 119B 43.98B 393B 40.89B 40.08B 1,661B EV / Sales 2024 *
2.7x
EV / Sales 2025 * 2.21x
Free-Float
97.06%
Yield 2024 *
-
Yield 2025 * -
More valuation ratios * Estimated data
Dynamic Chart
1 day+3.88%
1 week+3.43%
Current month+1.15%
1 month+2.14%
3 months-1.04%
6 months+16.30%
Current year+2.15%
More quotes
1 week
119.12
Extreme 119.12
126.76
1 month
118.92
Extreme 118.915
127.14
Current year
118.72
Extreme 118.72
127.14
1 year
99.06
Extreme 99.06
134.17
3 years
99.06
Extreme 99.06
169.98
5 years
86.88
Extreme 86.88
189.00
10 years
86.88
Extreme 86.88
194.73
More quotes
Director TitleAgeSince
Chief Executive Officer 61 24/10/2019
Director of Finance/CFO 60 29/02/2024
President 53 30/09/2023
Manager TitleAgeSince
Chairman 61 24/10/2019
Director/Board Member 64 17/01/2012
Director/Board Member 65 31/12/2009
More insiders
Add to a list
Change 5d. change 1-year change 3-years change Capi.($)
+3.87%+3.43%+1.26%-11.38% 7.47B
-0.16%+5.06%+17.72%+268.15% 782B
-2.47%+1.28%-27.74%+83.27% 378B
+1.13%+1.73%-1.08%-6.89% 371B
+0.31%+0.51%+10.32%+34.44% 336B
-0.83%+0.77%+26.68%-17.36% 256B
-0.80%+5.39%+22.35%+36.59% 225B
+1.13%+2.56%+11.82%+22.90% 210B
+0.02%+1.90%+0.03%+29.06% 158B
-1.26%-1.18%-7.57%-49.66% 147B
Average +0.11%+2.19%+5.38%+38.91% 287.18B
Weighted average by Cap. -0.28%+3.44%+6.86%+89.18%
See all sector performances

Financials

2024 *2025 *
Net sales 4.04B 3.9B 3.69B 3.25B 5.78B 351B 6.42B 43.89B 16.29B 146B 15.14B 14.84B 615B 4.34B 4.19B 3.96B 3.49B 6.21B 377B 6.89B 47.14B 17.49B 156B 16.26B 15.94B 661B
Net income 519M 502M 474M 418M 743M 45.07B 825M 5.64B 2.09B 18.72B 1.95B 1.91B 79.08B 603M 582M 550M 485M 862M 52.29B 957M 6.55B 2.43B 21.72B 2.26B 2.21B 91.75B
Net Debt 3.44B 3.33B 3.14B 2.77B 4.93B 299B 5.47B 37.41B 13.88B 124B 12.9B 12.65B 524B 2.13B 2.06B 1.95B 1.72B 3.05B 185B 3.39B 23.18B 8.6B 76.92B 8B 7.84B 325B
More financial data * Estimated data
Logo Jazz Pharmaceuticals plc
Jazz Pharmaceuticals PLC is a biotechnology company. The Company is engaged in developing medicines for people with serious diseases. The Company’s lead marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Xyrem (sodium oxybate) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Defitelio (defibrotide sodium) AND Vyxeos (daunorubicin and cytarabine) liposome for injection. The Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution product is for the treatment of cataplexy or excessive daytime sleepiness (EDS), in patients with narcolepsy seven years of age and older. The Xyrem (sodium oxybate) oral solution product is for the treatment of cataplexy or EDS in patients with narcolepsy seven years of age and older. The Defitelio (defibrotide sodium) product is for the treatment of hepatic veno-occlusive disease (VOD).
Employees
2,800
More about the company
Date Price Change Volume
11/02/25 126.76 $ +2.63% 172,933
10/02/25 123.51 $ +2.68% 856,837
07/02/25 120.29 $ +0.18% 615,903
06/02/25 120.07 $ -1.20% 461,720
05/02/25 121.53 $ -0.08% 499,838

Delayed Quote Nasdaq, February 11, 2025 at 05:43 pm

More quotes
Trading Rating
Investor Rating
ESG MSCI
A
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
123.51USD
Average target price
181.37USD
Spread / Average Target
+46.85%
Consensus

Quarterly revenue - Rate of surprise